Ligand id: 7393

Name: tasimelteon

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 38.33
Molecular weight 245.14
XLogP 2.45
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to treat blind patients suffering from non-24-hour sleep–wake disorder. In the EU, the EMA has granted this drug orphan designation for the treatment of non-24-hour sleep-wake disorder.
Mechanism Of Action and Pharmacodynamic Effects
Tasimelteon is a selective agonist for the melatonin MT1 and MT2 receptors. This drug effectively improves the onset and maintenance of sleep in blind patients who suffer from circadian rhythm sleep disorders due to an absence of photic input.
External links